Discover Koneksa

Obtain a PDF overview of our company and offerings.

Digital Biomarkers Tailored Around Parkinson’s Patients Better Data. Faster Results.

Digital Biomarkers
Tailored Around
Parkinson's Patients

Better Data. Faster Results.

koneksa elderly person

Digital biomarkers have brought new levels of speed and accuracy to the world of Parkinson’s clinical trials, producing better data with the potential to accelerate clinical trial timelines with increasingly confident decisions.

Koneksa stands at the forefront of this evolution, developing and validating digital biomarkers enhanced by cutting-edge algorithms for early signal detection and built for specific therapeutic considerations, such as Parkinson’s disease. Alongside a configurable SaaS platform, Koneksa is uniquely suited to provide advanced effect detection solutions and quicker, more actionable results for Parkinson’s disease research.

line dash circle

What We Offer Parkinson’s Research

Our science-driven approach results in highly specialized digital biomarkers designed for faster, more comprehensive data collection. This allows for early signal detection as well as optimal patient centricity for exceptional compliance and a more complete picture of each patient and data set.

Additionally, our digital measures benefit from more objective remote data collection that minimizes human bias and error, as traditional assessments are subjective, relying on the clinician to correctly quantify tremor level or balance changes. Our digital biomarkers garner timely, accurate reporting of the measures that matter, resulting in quicker, deeper insights at every level.

Combined with over 7 years of regulatory experience showing proven success and unique expertise, our work in Parkinson’s research provides targeted benefits that offset the challenges inherent in traditional Neuroscience trials:

Seamless remote data collection leveraging trusted digital health technology — lowers patient burden, increases convenience, and improves compliance

Evidence that guides for future success in Parkinson’s research — thorough data sets that show which protocols produced the most compliance

A dynamic, device-agnostic platform — crucial for a disease with vast symptoms and no “average patient”

Clearer data capture — faster, more comprehensive data for more confident decision-making

A higher standard in quality data — a higher frequency of collection than MDS-UPDRS and other standard measures

More robust proprietary algorithms — aligned with innovative capabilities to produce better data in less time

line circle
waves

The Future of Parkinson’s Disease Research Starts Here

Koneksa is THE digital biomarker company, leading and defining how the life sciences industry uses digital measurement solutions to transform clinical research in a precise and clinically robust manner. Going far beyond conventional eCOAs, our offerings include user-friendly, app-based functional assessments, passively collected wearable sensor data, and a configurable, SaaS study execution platform to support seamless compliance monitoring, data integration, and device provisioning.

The future of Parkinson’s research will be defined by continuous remote data collection that not only respects the needs of Parkinson’s patients but also produces more meaningful everyday clinical measures for study endpoint analysis and milestone evaluation. It will be defined by better data and faster results — made possible by Koneksa’s digital biomarkers.

Connect With Koneksa